A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
Novartis
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Dragonfly Therapeutics
Fred Hutchinson Cancer Center
Exelixis
M.D. Anderson Cancer Center
University of Chicago
Replimune Inc.
Myeloid Therapeutics
Ohio State University Comprehensive Cancer Center
Genentech, Inc.
Hefei TG ImmunoPharma Co., Ltd.
National Cancer Institute (NCI)
Bristol-Myers Squibb
University of California, San Diego
Tesaro, Inc.
Nanobiotix
Memorial Sloan Kettering Cancer Center
Memgen, Inc.
University of Maryland, Baltimore
M.D. Anderson Cancer Center
DEKA Biosciences
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Exelixis
Compugen Ltd
Navire Pharma Inc., a BridgeBio company
Eli Lilly and Company
Molecular Templates, Inc.
Celgene
Ono Pharmaceutical Co. Ltd
Yale University
Pfizer
Celgene
Biomica Ltd.
H. Lee Moffitt Cancer Center and Research Institute
Rutgers, The State University of New Jersey
Bayer
Roswell Park Cancer Institute
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Tempest Therapeutics
Assistance Publique Hopitaux De Marseille
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Second Affiliated Hospital, School of Medicine, Zhejiang University